HC Wainwright restated their buy rating on shares of Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) in a report published ...

Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Syndax ...

Highlights,Target price adjustments for Syndax Pharmaceuticals reflect varied market sentiment.,Executive decisions on stock ...

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on March 1, 2025 the Company granted ...

NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today ...

At the close in NYSE,... Top Gainers: CMRX +14.1%. BBDO +6.4%. AKAO +5%. LPL +4.9%. SNDX +4.8%.Top Losers: LOOP -13.4%. GEMP -8.4%. DY -5.9%. GGB -4.9%. AGLE -4.9%.Now read: Achaogen Bags NTAP ...

After hours: March 7 at 6:38:22 PM EST Loading Chart for SNDX ...

After hours: March 7 at 6:38:22 p.m. EST ...

Highlights,Stronger Penalties,– Increased fines and imprisonment for insider trading violations.,Enhanced SEC Authority,– ...